PIP5KL1
gene geneOn this page
Also known as bA203J24.5MGC46424PIPKH
Summary
PIP5KL1 (phosphatidylinositol-4-phosphate 5-kinase like 1, HGNC:28711) is a protein-coding gene on chromosome 9q34.11, encoding Phosphatidylinositol 4-phosphate 5-kinase-like protein 1 (Q5T9C9). May act as a scaffold to localize and regulate type I PI(4)P 5-kinases to specific compartments within the cell, where they generate PI(4,5)P2 for actin nucleation, signaling and scaffold protein recruitment and conversion to PI(3,4,5)P3.
PIP5KL1 is a phosphoinositide kinase-like protein that lacks intrinsic lipid kinase activity but associates with type I PIPKs (see PIP5K1A; MIM 603275) and may play a role in localization of PIPK activity (Chang et al., 2004 [PubMed 14701839]).
Source: NCBI Gene 138429 — RefSeq curated summary.
At a glance
- GWAS associations: 1
- Clinical variants (ClinVar): 64 total
- MANE Select transcript:
NM_001135219
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:28711 |
| Approved symbol | PIP5KL1 |
| Name | phosphatidylinositol-4-phosphate 5-kinase like 1 |
| Location | 9q34.11 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | bA203J24.5, MGC46424, PIPKH |
| Ensembl gene | ENSG00000167103 |
| Ensembl biotype | protein_coding |
| OMIM | 612865 |
| Entrez | 138429 |
Gene structure
Transcript identifiers
Ensembl transcripts: 12 — 10 protein_coding_CDS_not_defined, 2 protein_coding
ENST00000300432, ENST00000388747, ENST00000464108, ENST00000464759, ENST00000476624, ENST00000477191, ENST00000485562, ENST00000490773, ENST00000492296, ENST00000495448, ENST00000497234, ENST00000498783
RefSeq mRNA: 2 — MANE Select: NM_001135219
NM_001135219, NM_173492
CCDS: CCDS48030, CCDS6885
Canonical transcript exons
ENST00000388747 — 10 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001843550 | 127920881 | 127922114 |
| ENSE00002288474 | 127930723 | 127930777 |
| ENSE00003520527 | 127927153 | 127927208 |
| ENSE00003529788 | 127929688 | 127929885 |
| ENSE00003546523 | 127928065 | 127928219 |
| ENSE00003568140 | 127925867 | 127925979 |
| ENSE00003644117 | 127928433 | 127928483 |
| ENSE00003645938 | 127925107 | 127925260 |
| ENSE00003670317 | 127927297 | 127927331 |
| ENSE00003692337 | 127927648 | 127927772 |
Expression profiles
Bgee: expression breadth ubiquitous, 158 present calls, max score 83.72.
FANTOM5 (CAGE): breadth broad, TPM avg 0.5574 / max 136.5879, expressed in 232 samples.
FANTOM5 promoters (6 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 102621 | 0.1590 | 55 |
| 102623 | 0.1543 | 72 |
| 102620 | 0.1280 | 39 |
| 102618 | 0.0815 | 47 |
| 102622 | 0.0252 | 8 |
| 102619 | 0.0093 | 2 |
Top tissues by expression
249 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| upper arm skin | UBERON:0004263 | 83.72 | gold quality |
| lower esophagus mucosa | UBERON:0035834 | 81.46 | gold quality |
| bone marrow cell | CL:0002092 | 77.69 | gold quality |
| left ventricle myocardium | UBERON:0006566 | 76.69 | gold quality |
| cardiac muscle of right atrium | UBERON:0003379 | 76.68 | gold quality |
| parotid gland | UBERON:0001831 | 75.28 | gold quality |
| olfactory segment of nasal mucosa | UBERON:0005386 | 73.88 | gold quality |
| skin of abdomen | UBERON:0001416 | 73.80 | gold quality |
| stromal cell of endometrium | CL:0002255 | 73.24 | gold quality |
| esophagus mucosa | UBERON:0002469 | 72.97 | gold quality |
| cortical plate | UBERON:0005343 | 72.69 | gold quality |
| prefrontal cortex | UBERON:0000451 | 72.43 | gold quality |
| skin of leg | UBERON:0001511 | 72.32 | gold quality |
| ventricular zone | UBERON:0003053 | 72.26 | gold quality |
| pituitary gland | UBERON:0000007 | 71.70 | gold quality |
| primordial germ cell in gonad | CL:0000670 ∩ UBERON:0000991 | 71.54 | gold quality |
| adenohypophysis | UBERON:0002196 | 71.09 | gold quality |
| epithelial cell of pancreas | CL:0000083 | 70.81 | gold quality |
| zone of skin | UBERON:0000014 | 70.73 | gold quality |
| ectocervix | UBERON:0012249 | 70.58 | gold quality |
| saliva-secreting gland | UBERON:0001044 | 70.36 | gold quality |
| minor salivary gland | UBERON:0001830 | 70.06 | gold quality |
| mucosa of stomach | UBERON:0001199 | 69.85 | gold quality |
| vagina | UBERON:0000996 | 69.62 | gold quality |
| right frontal lobe | UBERON:0002810 | 69.61 | gold quality |
| nasal cavity epithelium | UBERON:0005384 | 69.52 | gold quality |
| esophagus | UBERON:0001043 | 69.09 | gold quality |
| right hemisphere of cerebellum | UBERON:0014890 | 68.99 | gold quality |
| anterior cingulate cortex | UBERON:0009835 | 68.91 | gold quality |
| kidney epithelium | UBERON:0004819 | 68.63 | gold quality |
Single-cell (SCXA)
Detected in 2 experiment(s), a significant marker in 0.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-GEOD-36552 | no | 19.10 |
| E-ANND-3 | no | 2.47 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
19 targeting PIP5KL1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-3605-5P | 99.96 | 67.12 | 932 |
| HSA-MIR-9718 | 99.94 | 68.91 | 918 |
| HSA-MIR-6753-3P | 99.93 | 66.57 | 637 |
| HSA-MIR-7107-3P | 99.93 | 66.73 | 627 |
| HSA-MIR-3686 | 99.90 | 70.53 | 2432 |
| HSA-MIR-137-3P | 99.87 | 74.74 | 2401 |
| HSA-MIR-4527 | 99.66 | 67.43 | 714 |
| HSA-MIR-7157-5P | 99.66 | 69.33 | 1829 |
| HSA-MIR-6503-5P | 99.62 | 66.96 | 597 |
| HSA-MIR-4310 | 99.59 | 68.84 | 2527 |
| HSA-MIR-1252-3P | 99.55 | 67.71 | 2862 |
| HSA-MIR-3123 | 99.47 | 67.15 | 2693 |
| HSA-MIR-4311 | 99.31 | 70.47 | 3041 |
| HSA-MIR-338-3P | 98.14 | 67.38 | 1137 |
| HSA-MIR-556-5P | 97.75 | 66.17 | 473 |
| HSA-MIR-8055 | 97.62 | 66.09 | 1023 |
| HSA-MIR-610 | 96.84 | 67.98 | 905 |
| HSA-MIR-3679-5P | 94.75 | 66.46 | 862 |
| HSA-MIR-1185-5P | 94.47 | 65.95 | 725 |
Literature-anchored findings (GeneRIF, showing 3)
- PIPKH acts as a scaffold to localize and regulate type I PI(4)P 5-kinases and the synthesis of PI(3,4,5)P(3) (PMID:14701839)
- These studies indicate a functional negative correlation between elevated levels of PIP5KL1 and the development of human gastric cancer. (PMID:19680787)
- Enforced expression of phosphatidylinositol 4-phosphate 5-kinase homolog alters PtdIns(4,5)P2 distribution and the localization of small G-proteins. (PMID:31616009)
Cross-species orthologs
3 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | pip5kl1 | ENSDARG00000060946 |
| mus_musculus | Pip5kl1 | ENSMUSG00000046854 |
| rattus_norvegicus | Pip5kl1 | ENSRNOG00000048676 |
Paralogs (6): PIP5K1B (ENSG00000107242), PIP5K1A (ENSG00000143398), PIP4K2A (ENSG00000150867), PIP4K2C (ENSG00000166908), PIP5K1C (ENSG00000186111), PIP4K2B (ENSG00000276293)
Protein
Protein identifiers
Phosphatidylinositol 4-phosphate 5-kinase-like protein 1 — Q5T9C9 (reviewed: Q5T9C9)
All UniProt accessions (1): Q5T9C9
UniProt curated annotations — full annotation on UniProt →
Function. May act as a scaffold to localize and regulate type I PI(4)P 5-kinases to specific compartments within the cell, where they generate PI(4,5)P2 for actin nucleation, signaling and scaffold protein recruitment and conversion to PI(3,4,5)P3.
Subunit / interactions. Heterodimerizes with other type I phosphatidylinositol 4-phosphate 5-kinase.
Subcellular location. Cytoplasm. Membrane.
Isoforms (2)
| UniProt ID | Names | Canonical? |
|---|---|---|
| Q5T9C9-1 | 1 | yes |
| Q5T9C9-2 | 2 |
RefSeq proteins (2): NP_001128691, NP_775763 (=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR002498 | PInositol-4-P-4/5-kinase_core | Domain |
| IPR023610 | PInositol-4/5-P-5/4-kinase | Family |
| IPR027483 | PInositol-4-P-4/5-kinase_C_sf | Homologous_superfamily |
| IPR027484 | PInositol-4-P-5-kinase_N | Homologous_superfamily |
Pfam: PF01504
Catalyzed reactions (Rhea), 1 shown:
- a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol 4-phosphate) + ATP = a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-4,5-bisphosphate) + ADP + H(+) (RHEA:14425)
UniProt features (3 total): chain 1, domain 1, splice variant 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q5T9C9-F1 | 85.21 | 0.66 |
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 96 (showing top):
GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_MCMV_INFECTION_DN, GOBP_PHOSPHOLIPID_METABOLIC_PROCESS, GOBP_PHOSPHATIDYLINOSITOL_METABOLIC_PROCESS, GOBP_ORGANOPHOSPHATE_METABOLIC_PROCESS, GOBP_ORGANOPHOSPHATE_BIOSYNTHETIC_PROCESS, GOBP_NEGATIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION, GOBP_PHOSPHOLIPID_BIOSYNTHETIC_PROCESS, GOBP_GLYCEROLIPID_METABOLIC_PROCESS, GOBP_NEGATIVE_REGULATION_OF_PHOSPHATIDYLINOSITOL_3_KINASE_PROTEIN_KINASE_B_SIGNAL_TRANSDUCTION, GOBP_PHOSPHATIDYLINOSITOL_3_KINASE_PROTEIN_KINASE_B_SIGNAL_TRANSDUCTION, GOBP_GLYCEROLIPID_BIOSYNTHETIC_PROCESS, GOBP_GLYCEROPHOSPHOLIPID_METABOLIC_PROCESS, GOBP_LIPID_METABOLIC_PROCESS, GOBP_LIPID_BIOSYNTHETIC_PROCESS, GOBP_REGULATION_OF_MITOCHONDRIAL_MEMBRANE_POTENTIAL
GO Biological Process (8): negative regulation of mitochondrial membrane potential (GO:0010917), negative regulation of cell migration (GO:0030336), positive regulation of apoptotic process (GO:0043065), phosphatidylinositol phosphate biosynthetic process (GO:0046854), negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction (GO:0051898), lipid metabolic process (GO:0006629), regulation of signal transduction (GO:0009966), phosphatidylinositol metabolic process (GO:0046488)
GO Molecular Function (6): ATP binding (GO:0005524), 1-phosphatidylinositol-4-phosphate 5-kinase activity (GO:0016308), nucleotide binding (GO:0000166), kinase activity (GO:0016301), transferase activity (GO:0016740), phosphatidylinositol kinase activity (GO:0052742)
GO Cellular Component (5): cytosol (GO:0005829), plasma membrane (GO:0005886), cell projection (GO:0042995), cytoplasm (GO:0005737), membrane (GO:0016020)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| cellular anatomical structure | 4 |
| negative regulation of membrane potential | 1 |
| regulation of mitochondrial membrane potential | 1 |
| cell migration | 1 |
| regulation of cell migration | 1 |
| negative regulation of cell motility | 1 |
| apoptotic process | 1 |
| regulation of apoptotic process | 1 |
| positive regulation of programmed cell death | 1 |
| glycerophospholipid biosynthetic process | 1 |
| phosphatidylinositol 3-kinase/protein kinase B signal transduction | 1 |
| regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction | 1 |
| negative regulation of intracellular signal transduction | 1 |
| primary metabolic process | 1 |
| signal transduction | 1 |
| regulation of cell communication | 1 |
| regulation of signaling | 1 |
| regulation of response to stimulus | 1 |
| phosphorus metabolic process | 1 |
| adenyl ribonucleotide binding | 1 |
| purine ribonucleoside triphosphate binding | 1 |
| phosphatidylinositol kinase activity | 1 |
| nucleoside phosphate binding | 1 |
| heterocyclic compound binding | 1 |
| transferase activity, transferring phosphorus-containing groups | 1 |
| catalytic activity | 1 |
| lipid kinase activity | 1 |
| phosphotransferase activity, alcohol group as acceptor | 1 |
| cytoplasm | 1 |
| membrane | 1 |
| cell periphery | 1 |
| intracellular anatomical structure | 1 |
Protein interactions and networks
STRING
684 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| PIP5KL1 | ANKRD13B | Q86YJ7 | 512 |
| PIP5KL1 | PIP5K1A | Q99755 | 499 |
| PIP5KL1 | TMEM25 | Q86YD3 | 491 |
| PIP5KL1 | TMEM91 | Q6ZNR0 | 451 |
| PIP5KL1 | USP17L7 | P0C7H9 | 448 |
| PIP5KL1 | TMEM117 | Q9H0C3 | 441 |
| PIP5KL1 | MBOAT1 | Q6ZNC8 | 405 |
| PIP5KL1 | GRIFIN | A4D1Z8 | 403 |
| PIP5KL1 | EEIG1 | Q5T9C2 | 400 |
| PIP5KL1 | DPM2 | O94777 | 398 |
| PIP5KL1 | PIK3CD | O00329 | 394 |
| PIP5KL1 | PLPPR3 | Q6T4P5 | 364 |
| PIP5KL1 | GPR160 | Q9UJ42 | 355 |
| PIP5KL1 | USP53 | Q70EK8 | 342 |
| PIP5KL1 | EML1 | O00423 | 338 |
IntAct
3 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| PIP5KL1 | HSPA9 | psi-mi:“MI:0915”(physical association) | 0.400 |
| PIP5KL1 | ABCF3 | psi-mi:“MI:0915”(physical association) | 0.400 |
BioGRID (5): PIP5K1B (Affinity Capture-Western), PIP5K1C (Affinity Capture-Western), PIP5K1A (Affinity Capture-Western), PIP5KL1 (Proximity Label-MS), ABCF3 (Affinity Capture-MS)
ESM2 similar proteins: A4FV98, A5PK51, A6NDG6, E1BE10, O00587, O35595, O95294, P60487, Q12788, Q17QS4, Q1JPJ0, Q2T9S4, Q2TBI8, Q32NY4, Q3T063, Q3ZBF9, Q501J2, Q5E9V4, Q5F4B1, Q5IS64, Q5SUV1, Q5T9C9, Q6AYG0, Q6AYR8, Q6XQN1, Q6XQN6, Q6ZMM2, Q80US4, Q8BNV1, Q8BZG5, Q8CC86, Q8IZ69, Q8N9H8, Q8NE01, Q8R2H9, Q8TCT1, Q8VCA8, Q8VD52, Q969S8, Q96AZ1
Diamond homologs: B0G126, Q17QS4, Q5T9C9, Q6U7H8, Q9LMN1, Q9SSJ8, Q9LUM0, O48709, O96838, P38994, Q56YP2, Q6EX42, Q8L796, Q8L850, Q8RY89, Q9M149, Q9M1K2, Q9SFB8, Q9SLG9, Q9SUI2, O13853, O88377, Q0WUR5, Q55GN6, Q80XI4, Q9XID0
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
64 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 53 |
| Likely benign | 2 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
1799 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 9:127925101:GCTCA:G | donor_loss | 1.0000 |
| 9:127925102:CTCAC:C | donor_loss | 1.0000 |
| 9:127925103:TCACC:T | donor_loss | 1.0000 |
| 9:127925104:CACCT:C | donor_loss | 1.0000 |
| 9:127925105:ACCTG:A | donor_loss | 1.0000 |
| 9:127925106:C:CA | donor_loss | 1.0000 |
| 9:127925981:T:A | acceptor_loss | 1.0000 |
| 9:127927148:CTCA:C | donor_loss | 1.0000 |
| 9:127927150:CA:C | donor_loss | 1.0000 |
| 9:127927151:A:AC | donor_gain | 1.0000 |
| 9:127927152:C:CC | donor_gain | 1.0000 |
| 9:127927152:CCT:C | donor_gain | 1.0000 |
| 9:127927206:CGT:C | acceptor_gain | 1.0000 |
| 9:127927329:CTC:C | acceptor_gain | 1.0000 |
| 9:127927644:GTACC:G | donor_loss | 1.0000 |
| 9:127927646:A:AC | donor_gain | 1.0000 |
| 9:127927646:A:T | donor_loss | 1.0000 |
| 9:127927646:AC:A | donor_gain | 1.0000 |
| 9:127927647:C:CA | donor_loss | 1.0000 |
| 9:127927647:C:CC | donor_gain | 1.0000 |
| 9:127927647:CC:C | donor_gain | 1.0000 |
| 9:127927700:G:C | donor_gain | 1.0000 |
| 9:127927768:CGTGG:C | acceptor_gain | 1.0000 |
| 9:127927769:GTGG:G | acceptor_gain | 1.0000 |
| 9:127927770:TGG:T | acceptor_gain | 1.0000 |
| 9:127927770:TGGC:T | acceptor_loss | 1.0000 |
| 9:127927771:GG:G | acceptor_gain | 1.0000 |
| 9:127927772:GCT:G | acceptor_loss | 1.0000 |
| 9:127927773:C:CC | acceptor_gain | 1.0000 |
| 9:127927773:C:CG | acceptor_loss | 1.0000 |
AlphaMissense
2533 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 9:127925968:T:A | K221I | 0.997 |
| 9:127925967:T:A | K221N | 0.994 |
| 9:127925967:T:G | K221N | 0.994 |
| 9:127927748:C:A | K153N | 0.985 |
| 9:127927748:C:G | K153N | 0.985 |
| 9:127925892:G:C | N246K | 0.984 |
| 9:127925892:G:T | N246K | 0.984 |
| 9:127925901:C:A | K243N | 0.982 |
| 9:127925901:C:G | K243N | 0.982 |
| 9:127925181:G:C | S281R | 0.980 |
| 9:127925181:G:T | S281R | 0.980 |
| 9:127925183:T:G | S281R | 0.980 |
| 9:127925899:T:G | D244A | 0.976 |
| 9:127925969:T:C | K221E | 0.976 |
| 9:127925973:G:C | D219E | 0.976 |
| 9:127925973:G:T | D219E | 0.976 |
| 9:127925900:C:G | D244H | 0.974 |
| 9:127928214:G:C | F95L | 0.974 |
| 9:127928214:G:T | F95L | 0.974 |
| 9:127928216:A:G | F95L | 0.974 |
| 9:127925974:T:C | D219G | 0.973 |
| 9:127925974:T:G | D219A | 0.972 |
| 9:127925978:A:C | Y218D | 0.972 |
| 9:127928174:G:T | R109S | 0.972 |
| 9:127928103:G:C | F132L | 0.971 |
| 9:127928103:G:T | F132L | 0.971 |
| 9:127928105:A:G | F132L | 0.971 |
| 9:127927185:G:C | S206R | 0.970 |
| 9:127927185:G:T | S206R | 0.970 |
| 9:127927187:T:G | S206R | 0.970 |
dbSNP variants (sampled 300 via entrez): RS1000048528 (9:127923478 C>G), RS1000268301 (9:127923661 CCAA>C), RS1000997704 (9:127930149 G>A), RS1001032846 (9:127923707 G>A,C), RS1001035524 (9:127921812 A>T), RS1001124699 (9:127927703 G>A,C), RS1001836891 (9:127932609 C>G), RS1001899461 (9:127932190 A>C), RS1002057554 (9:127920554 C>T), RS1002381954 (9:127929379 C>G), RS1002432772 (9:127929753 T>A), RS1003116633 (9:127926667 C>T), RS1003249198 (9:127930941 G>A,C), RS1003362980 (9:127921243 G>A), RS1003387196 (9:127927932 A>G)
Disease associations
OMIM: gene MIM:612865 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
1 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST005951_65 | Body mass index | 5.000000e-09 |
EFO canonical traits (1, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0004340 | body mass index |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
16 total (human), top 16 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| aristolochic acid I | decreases expression | 1 |
| bisphenol A | decreases expression | 1 |
| sodium arsenite | increases abundance, affects cotreatment, decreases expression | 1 |
| perfluorooctanoic acid | increases expression | 1 |
| 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline | decreases expression | 1 |
| clothianidin | decreases expression | 1 |
| bisphenol S | increases methylation | 1 |
| jinfukang | affects cotreatment, increases expression | 1 |
| Microplastics | decreases expression, increases abundance | 1 |
| Arsenic | affects cotreatment, decreases expression, increases abundance | 1 |
| Cisplatin | affects cotreatment, increases expression | 1 |
| Polyethylene Terephthalates | decreases expression, increases abundance | 1 |
| Rotenone | increases expression | 1 |
| Smoke | decreases expression | 1 |
| Valproic Acid | increases methylation | 1 |
| Okadaic Acid | decreases expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.